During the serious recession of 2008 and 2009, the healthcare industry was one of the few actual growth areas, just as the USA was in the news due to the president’s intended healthcare reform and the consequent, lengthy delays in Congress. During Pres. Obama’s successful campaign, the healthcare business was much in the news and upon inauguration he pushed both houses of Congress to act quickly and with credibility. It appears as if we are poised on the edge of a momentous change in the industry, which will affect everyone involved from healthcare providers through hospitals, insurance companies and pharmaceutical companies. In these tumultuous times, the role of healthcare and pharmaceutical consulting organisations will be pivotal and all the skills possessed by these companies will be necessary as changes are processed and results analysed.
Healthcare can be seen as a growth industry for a considerable time ahead as the baby boomer generation starts to age and comes to a period when more strain is likely to be placed on the healthcare system. A pharmaceutical company will need to be on its toes, innovative and ready to provide additional products and services. Competition in the marketplace is sure to evolve.
A spotlight will always be trained on costs and the role of the insurance company as intermediary between both ends of the spectrum. Healthcare professionals are sure to receive pressure, as they weigh up the advice that they should give their patients in the light of new rules and rafts of legislation. In short, a period of uncertainty can be expected to add even more pressures to an already pressure packed environment.
In the time to come, pharmaceutical consultants will be more valuable than ever as pharma consulting plays its role in deciphering new and complex rules and positions. A company’s workforce will benefit from the training provided by these consultants, as they deliver results and draw on years of experience, training and expertise. Executives from the parent company must spend as much time as possible dealing with the principal concerns associated with production and regulation. They should devote valuable time to staff administration, maintenance and training. The pharmaceutical consulting firm is ready and able to take on this element of the organisation and to ensure that sales executives implement correctly and bring as valuable a return as possible to the company’s bottom line.
There are few industries as dynamic as the healthcare business and pharmaceutical and healthcare consulting plays such a crucial business role within. Not all organisations interested in the development of a pharmaceutical company can be classified as “friendly” and this puts significant pressures on the company. While the company’s executives struggle with these issues, figuring out how to interpret positions and trying to devise how to approach and deal with each party from a strong position, the pharmaceutical consulting firm can provide valuable backing. The consultant can be a valuable ally and an extra pair of eyes and ears, to help the pharmaceutical company navigate through challenging, risky, yet potentially lucrative times ahead. The company is advised to consider a long-term engagement with the pharmaceutical and healthcare consulting firm accordingly.
Alan Gillies is the CEO of L2L Consulting, a cutting-edge pharma consultancy firm which specialises in optimising productivity and performance within international companies by applying tailored organisational strategies.